<DOC>
	<DOCNO>NCT00138242</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel together carboplatin work treat patient ovarian epithelial , fallopian tube , peritoneal cavity cancer .</brief_summary>
	<brief_title>Docetaxel Carboplatin Treating Patients With Ovarian Epithelial , Fallopian Tube , Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether weekly administration docetaxel carboplatin safer conventional three-week chemotherapy course , term reduce rate myelosuppression , patient stage IC-IV ovarian epithelial , fallopian tube , peritoneal cavity cancer . Secondary - Determine quality life patient treat regimen . - Determine toxic effect regimen patient . - Determine efficacy regimen , term clinical response rate , time disease progression , finding second-look surgery , patient . OUTLINE : Patients receive docetaxel IV carboplatin IV day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients may undergo optional second-look surgery . After completion 6 course chemotherapy ( second-look surgery , applicable ) , patient may receive consolidation and/or salvage therapy discretion investigator . Quality life assess baseline , treatment course , completion study treatment , annually 2 year . After completion study treatment , patient follow annually 2 year . PROJECTED ACCRUAL : A total 30 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , peritoneal cavity cancer Stage ICIV disease No borderline low malignant potential tumor stage Underwent initial surgical management , include staging , early stage disease surgical debulking advance stage disease* NOTE : *Patients may delay surgical debulking , clinically indicate , study entry ; patient may receive several course neoadjuvant chemotherapy prior surgical debulking , study entry PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal Meets 1 follow criterion : Alkaline phosphatase ( AP ) normal AND AST ALT ≤ 5 time upper limit normal ( ULN ) AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal Renal Not specify Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No peripheral neuropathy &gt; grade 1 No prior malignancy poor prognosis risk relapse study participation , determine principal investigator No history severe hypersensitivity reaction drug formulate polysorbate 80 PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No concurrent chemotherapy another malignancy Endocrine therapy Not specify Radiotherapy Not specify Surgery See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>